Case report: artificial elevation of prothrombin time by telavancin.
Amanatullah DF, Lopez MJ, Gosselin RC, Gupta MC.
Clin Orthop Relat Res · journal article; case reports; case-report · DOI 10.1007/s11999-012-2612-0 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för telavancin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
24 hitsIn vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.
Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM.
Diagn Microbiol Infect Dis · journal article · DOI 10.1016/j.diagmicrobio.2012.08.010Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME.
PLoS One · meta-analysis; research-article; systematic review; journal article · DOI 10.1371/journal.pone.0041870Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00922-12Transplacental transfer of vancomycin and telavancin.
Nanovskaya T, Patrikeeva S, Zhan Y, Fokina V, Hankins GD, Ahmed MS.
Am J Obstet Gynecol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ajog.2012.06.064Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions.
LaPlante KL, Woodmansee S, Mermel LA.
Am J Health Syst Pharm · research support, non-u.s. gov't; journal article · DOI 10.2146/ajhp110256Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC, Corey GR, Stryjewski ME.
Expert Rev Anti Infect Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/eri.12.81Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
Rose WE, Fallon M, Moran JJ, Vanderloo JP.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00676-12Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Marconescu P, Graviss EA, Musher DM.
Scand J Infect Dis · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.3109/00365548.2012.669843Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem.
Brinkman MB, Fan K, Shiveley RL, Van Anglen LJ.
Ann Pharmacother · journal article; case reports · DOI 10.1345/aph.1q331Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.
Lin G, Pankuch GA, Appelbaum PC, Kosowska-Shick K.
Diagn Microbiol Infect Dis · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.diagmicrobio.2012.04.003Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
Mendes RE, Sader HS, Farrell DJ, Jones RN.
Antimicrob Agents Chemother · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1128/aac.00011-12In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.
Hornsey M, Longshaw C, Phee L, Wareham DW.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.05870-11New therapy options for MRSA with respiratory infection/pneumonia.
Ramirez P, Fernández-Barat L, Torres A.
Curr Opin Infect Dis · review; journal article · DOI 10.1097/qco.0b013e3283509cfaTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
Hooper CY, Smith WJ.
Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s23247Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR.
J Antimicrob Chemother · meta-analysis; research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dks081Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies.
Song Y, Lunde CS, Benton BM, Wilkinson BJ.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.05403-11Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P.
Antimicrob Agents Chemother · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1128/aac.05915-11Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.
Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00383-11Acute renal insufficiency during telavancin therapy in clinical practice.
Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK.
J Antimicrob Chemother · journal article · DOI 10.1093/jac/dkr518Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Steed ME, Vidaillac C, Rybak MJ.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; evaluation study; journal article · DOI 10.1128/aac.05849-11Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Mendes RE, Sader HS, Farrell DJ, Jones RN.
Diagn Microbiol Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.diagmicrobio.2011.09.023Management of gram-positive bacterial infections in patients with cancer.
Kosmidis CI, Chandrasekar PH.
Leuk Lymphoma · review; journal article · DOI 10.3109/10428194.2011.602770Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
Antimicrob Agents Chemother · comparative study; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1128/aac.01641-07